Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1
Published: 18 Dec 2019
Views: 4005
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Dr Ian Krop gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the latest results from the DENSITY-Breast01 study.
Watch our interview with Dr Krop here.
Read more about the study here.
Related Videos
ecancer special issue on immunotherapy
Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy
3 Dec 2020
OncoAlert and ecancer weekly roundup for October 26 - 31, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
2 Nov 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
25 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
OncoAlert and ecancer weekly roundup for August 17-23 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
24 Aug 2020
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive b...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
19 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
18 Dec 2019
